Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastien J Hotte

Showing results (41-50 of 86) with videos related to

Pageof 9
Sort By:
Current Oncology (Toronto, Ont.)|July 28, 2023
The Use of Salvage Chemotherapy for Patients with Relapsed Testicular Germ Cell Tumor (GCT) in Canada: A National SurveyEsmail M Al-Ezzi, Amer Zahralliyali, Aaron R Hansen, et al.
Dermatology and Therapy|March 17, 2023
Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert PanelKim A Papp, Barbara Melosky, Sandeep Sehdev, et al.
Targeted Oncology|February 12, 2019
Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520Remy B Verheijen, Diane A J van der Biessen, Sebastien J Hotte, et al.
The Lancet. Oncology|January 19, 2015
Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trialRicard Mesía, Michael Henke, Andre Fortin, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|January 2, 2015
Evaluation of second-line and subsequent targeted therapies in metastatic renal cell cancer (mRCC) patients treated with first-line cediranibSuzanne Richter, Jo-An Seah, Gregory R Pond, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2011
Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomasAnastasios Stathis, Sebastien J Hotte, Eric X Chen, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|August 28, 2020
Real-world management of advanced prostate cancer: A description of management practices of community-based physicians and prostate cancer specialistsSebastien J Hotte, Antonio Finelli, Kim N Chi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2026
Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1Mary-Ellen Taplin, Irbaz Bin Riaz, R Bryan Rumble, et al.
Investigational New Drugs|December 22, 2015
A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041)Joanne W Chiu, Sebastien J Hotte, Christian K Kollmannsberger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2011
Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomasAnastasios Stathis, Sebastien J Hotte, Eric X Chen, et al.
Pageof 9

Showing results (41-50 of 86) with videos related to

Sort By:
Pageof 9
Current Oncology (Toronto, Ont.)|July 28, 2023
The Use of Salvage Chemotherapy for Patients with Relapsed Testicular Germ Cell Tumor (GCT) in Canada: A National SurveyEsmail M Al-Ezzi, Amer Zahralliyali, Aaron R Hansen, et al.
Dermatology and Therapy|March 17, 2023
Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert PanelKim A Papp, Barbara Melosky, Sandeep Sehdev, et al.
Targeted Oncology|February 12, 2019
Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520Remy B Verheijen, Diane A J van der Biessen, Sebastien J Hotte, et al.
The Lancet. Oncology|January 19, 2015
Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trialRicard Mesía, Michael Henke, Andre Fortin, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|January 2, 2015
Evaluation of second-line and subsequent targeted therapies in metastatic renal cell cancer (mRCC) patients treated with first-line cediranibSuzanne Richter, Jo-An Seah, Gregory R Pond, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2011
Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomasAnastasios Stathis, Sebastien J Hotte, Eric X Chen, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|August 28, 2020
Real-world management of advanced prostate cancer: A description of management practices of community-based physicians and prostate cancer specialistsSebastien J Hotte, Antonio Finelli, Kim N Chi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2026
Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1Mary-Ellen Taplin, Irbaz Bin Riaz, R Bryan Rumble, et al.
Investigational New Drugs|December 22, 2015
A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041)Joanne W Chiu, Sebastien J Hotte, Christian K Kollmannsberger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2011
Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomasAnastasios Stathis, Sebastien J Hotte, Eric X Chen, et al.
Pageof 9